Table 1 Characteristics of female and male patients with a dual diagnosis of type 2 diabetes and cardiovascular disease 2012–2018
All (n = 70.538) | Female (n = 27.133) | Male (n = 43.405) | Missing values | |
|---|---|---|---|---|
Age in years (mean, SD) | 69.9 (11.9) | 72.1 (12.3) | 68.6 (11.3) | 0.0 |
Diabetes duration in years (mean, SD) | 3.7 (5.8) | 4.1 (6.1) | 3.5 (5.6) | 0.0 |
Education level (n, %) | 3.7a | |||
0–10 years | 26,358 (38.8) | 12,556 (48.5) | 13,802 (32.8) | |
10–15 years | 33,775 (49.7) | 11,048 (42.6) | 22,727 (54.1) | |
> 15 years | 7795 (11.5) | 2305 (8.9) | 5490 (13.1) | |
HbA1c mmol/mol (mean, SD) | 55 (16) | 54 (15) | 56 (16) | 22.4a |
LDL mol/l (mean, SD) | 2.3 (1.0) | 2.4 (1.1) | 2.3 (1.0) | 33.1a |
Estimated GFR ml-min per 1.73m2 (mean, SD) | 69 (22) | 67 (22) | 71 (21) | 61.0a |
Use of cardioprotective glucose-lowering drug prior to or initiated at index date (n, %) | 3256 (4.6) | 1184 (4.4) | 2072 (4.8) | 0.0 |
Use of SGLT2 inhibitor prior to or initiated at index date (n, %) | 1005 (1.4) | 329 (1.2) | 676 (1.6) | 0.0 |
Use of GLP1 analogue prior to or initiated at index date (n, %) | 2565 (3.6) | 956 (3.5) | 1609 (3.7) | 0.0 |
Lipid-lowering drug (n, %) | 45,427 (64.4) | 16,719 (61.6) | 28,708 (66.1) | 0.0 |
Antihypertensive drug (n, %) | 60,376 (85.6) | 23,636 (87.1) | 36,740 (84.6) | 0.0 |
Antiplatelet or anticoagulant drug (n, %) | 45,923 (65.1) | 16,932 (62.4) | 28,991 (66.8) | 0.0 |
Latest diagnosis at index date (n, %) | 0.0 | |||
CVD | 32,178 (45.6) | 13,147 (48.5) | 19,031 (43.8) | |
CVD and T2D | 579 (0.8) | 176 (0.6) | 403 (0.9) | |
T2D | 37,781 (53.6) | 13,810 (50.9) | 23,971 (55.2) | |
CVD type (n, %) | 0.0 | |||
Ischemic heart disease | 34,443 (48.8) | 12,081 (44.5) | 22,362 (51.5) | |
Heart failure | 10,982 (15.6) | 4494 (16.6) | 6488 (14.9) | |
Peripheral arterial disease | 8583 (12.2) | 3410 (12.6) | 5173 (11.9) | |
Cerebrovascular disease | 16,530 (23.4) | 7148 (26.3) | 9382 (21.6) |